The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus ...

This study shows that therapeutic phages can be detected by epithelial cells of the human respiratory tract, eliciting proinflammatory responses that depend on specific phage properties and the airway ...

Armata Pharmaceuticals (ARMP) highlighted “positive” results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...

Investing.com -- Armata Pharmaceuticals (NYSE American:ARMP) stock surged 95% following the announcement of positive Phase 2a clinical trial results for its bacteriophage treatment targeting ...

One possible solution to the problem of antimicrobial resistant organisms is designing bacteriaphages, or simply phages, to ...

The 7th World Conference on Targeting Phage Therapy is being organized on June 20-21, 2024 at Corinthia Palace Malta with more than 20 international speakers. The 7 th World Conference on Targeting ...

Peering through his microscope in 1910, Franco-Canadian microbiologist Félix d'Hérelle noticed some "clear spots" in his bacterial cultures, an anomaly that turned out to be viruses preying on the ...

There’s nothing retro about retrons, which are bacterial molecules that produce DNA. Although retrons ordinarily serve an immune function in bacteria, they can, upon modification, acquire a genetic ...

Viruses of bacteria, known as bacteriophages or phages, were discovered nearly 100 years ago. Their potential as antibacterial agents was appreciated almost immediately, with the first 'phage therapy' ...

A pet cat named Squeaks has been saved from a multidrug-resistant infection with a pioneering therapy, a new study details. It marks the first ever use of personalized phage therapy in animals—a type ...

Collateral damage to normal microbiota, which can be associated with the use of less-specific chemical antibacterials, [4] is avoided. Nonetheless, there are several challenges that must be addressed ...